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6/j.bBasiliximab and daclizumab, two interleukin-2 receptor antagonists (IL-2RAs), prevent graft failure in renal
transplantation, which also effectively treat steroid-refractory graft-versus-host disease (GVHD). However,
only a few studies report that IL-2RAs prevent GVHD. Here we first retrospectively explored the prophy-
lactic effects of basiliximab or daclizumab against GVHD in 82 patients with hematologic malignancies follow-
ing unrelated donor-peripheral blood stem cell transplantation (URD-PBSCT). All recipients achieved
engraftment. The rates of grade II-IV and III-IV acute GVHD (aGVHD) were 35.4% and 15.9%, respectively.
Chronic GVHD (cGVHD) developed in 38.7% of evaluable patients. The transplantation-related mortality
was 13.4%, while relapse rate was 8.5%. The 2-year overall survival (OS) reached 77.1% and disease-free
survival (DFS) accumulated to 72.2%. The side effects of basiliximab and daclizumab were moderate and
tolerable. There were no significant differences in aGVHD onset and survival between the daclizumab
and basiliximab groups. However, basiliximab presented superior prophylactic effects on cGVHD than dacli-
zumab. In conclusion, basiliximab or daclizumab prevents GVHD efficiently and feasibly following URD-
PBSCT, and contributes to favorable outcome. Basiliximab has a similar effect on aGVHD but superior
activity against cGVHD. Further prospective and randomized control studies are needed.
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bmt.2011.09.005application. Fortunately, along with the development
of data banks of hematopoietic stem cell donors, the
Chinese patients have an increasing possibility of find-
ing alternative unrelated donors (URDs). However,
enhanced risk of graft-versus-host disease (GVHD) is
one of the major critical barriers to successful URD-
HSCT [1,2]. In the past decades, antithymocyte
globulin (ATG) has been combined with standard
GVHD prophylaxis regimens and significantly
reduced GVHD in URD-HSCT [3-6]. Nevertheless,
ATG targets multiple immunologic epitopes as
a lymphocyte-depleting polyclonal antibody. Admin-
istration of ATG pre- and peritransplantation not
only simultaneously depletes host and donor T cells
in vivo, but also affects additional cellular components
including B cells, natural killer cells, and antigen-
presenting cells. Thus, ATG is associated with side
effects such as prolonged immune deficiency and
increased incidence of infections, including cytomega-
lovirus (CMV) disease and Epstein-Barr virus-
associated posttransplant lympholiferative disease
(PTLD), which abrogates its positive impacts [4,5,7].
Moreover administration of ATG raises the cost of
Table 1. Patients’ Characteristics
Number of patients 82
Median age (range) 24 (12-53)
Sex (male/female) 43/39
Diagnosis and the status at transplantation
ALL 31
High WBC when first diagnosed 5
Ph+ 4
CNS leukemia 1
1st remission 24
$2nd remission 4
Refractory 3
AML 26
1st remission 20
$2nd remission 4
Refractory or evolution from MDS 2
HAL 3
CML 17
CP 16
AP 1
MDS 2
NHL 3
Time from diagnosis to transplantation, months (range) 8 (3-72)
Donor-recipient HLA type
6 of 6 matched on HLA-A, -B, and -DRB1 25
5 of 6 matched on HLA-A, -B, and -DRB1 37
#4/6 matched on HLA-A, -B, and -DRB1 20
Donor-recipient ABO blood type
Matched 27
Minor mismatched 25
Major mismatched 30
Conditioning regimen
BUCY 43
TBI + CY 11
BUCY + IDA or VP16 19
BUCY + Ara-c 9
GVHD prophylaxis
CsA + MTX + MMF + Anti-CD25 82
Median nucleated cell dose (108/kg) 7.2 (3.8-18.2)
Median CD34+ cell dose (106/kg) 5.8 (3.2-15.6)
Median follow-up time, months (range) 16.5 (2-72)
ALL indicates acute lymphoblastic leukemia; WBC, white blood cell; Ph,
Philadelphia chromosome; AML, acute myeloid leukemia; MDS, myelo-
dysplastic syndrome; HA, hybrid acute leukemia; CML, chronic myeloid
leukemia; CP, chronic phase; AP, accelerated phase; NHL, non-Hodgkin
lymphoma; HLA, human leukocyte antigen; 6 of 6 matched, identical at
allele or antigen level; 5 of 6 matched, single mismatch at allele level;#4
of 6 matched, 2 or more than 2 mismatches at allele level or single mis-
match at antigen level; TBI, total body irradiation; IDA, idarubicin; VP-16,
etoposide; Ara-C, cytarabine; MTX, methotrexate; MMF, mycopheno-
late mofetil; Anti-CD25, anti-CD25 monoclonal antibody.
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alternative immunosuppressive agents for GVHD
prophylaxis following URD-HSCT.
Both basiliximab and daclizumab are nonlympho-
cyte-depleting monoclonal antibodies targeting the
interleukin-2 receptor (IL-2R), which have been fre-
quently used to induce immunosuppression in solid or-
gan transplantation [8-10]. These interleukin-2
receptor antagonists (IL-2RAs) prevent acute rejection
without increasing infections andmalignancies in renal
transplantation [9,11]. Compared with ATG, IL-2RAs
have similar immunosuppressive efficacies but reduced
adverse effects in standard-risk recipients of renal
transplantation [9,11]. Furthermore, both daclizumab
and basiliximab increase quality-adjusted life-years
and decrease overall costs when assessing the cost-
effectiveness of the newer renal immunosuppressants
[12,13]. Therefore, IL-2R blockade provides an attrac-
tive option for the immunosuppression in solid organ
transplantation.
Recent studies reveal that IL-2Rcanbe thepotential
therapeutic target for GVHD [14]. The a-subunit of
IL-2R (CD25) has been found predominantly on the
surface of activated cytotoxic T cells. Specific binding
of monoclonal antibody to CD25 blocks the IL-2-in-
duced proliferation and provides selected immunosup-
pression [15]. Both basiliximab (chimeric anti-CD25
monoclonal antibody) and daclizumab (humanized
anti-CD25monoclonal antibody) have proven to be ef-
fective treatments for refractory or steroid-resistant/
dependent acute GVHD (aGVHD), in particular, for
cutaneous and low-moderate intestinal involvement
[14,16,17]. Moreover, few studies indicate that the
IL-2R blockade with basiliximab or daclizumab con-
tributes to GVHD prophylaxis in HSCT [18-22].
However, the documented cases are limited, and there
is no published study on the prophylactic activity of
basiliximab or daclizumab against GVHD following
URD-HSCT.
In the present retrospective study, basiliximab
or daclizumab was administrated in addition to
standard GVHD prophylaxis regimens in 82 patients
who received unrelated donor-peripheral blood stem
cell transplantation (URD-PBSCT). The aims of
this study were to evaluate hematologic recovery,
GVHD, transplantation-related mortality (TRM), re-
lapse, survival, and IL-2RAs-related toxicity. Our
results first provided the evidence that basiliximab or
daclizumab was effective and tolerable in preventing
GVHD following URD-PBSCT.DESIGN AND METHODS
Baseline Characteristics of Patients
Between July 2002 and January 2010, 82 consecu-
tive patients with hematologic malignancies receivedbasiliximab or daclizumab in addition to standard
GVHD prophylaxis regimens and underwent URD-
PBSCT in the Union Hospital of the Huazhong
University of Science and Technology. The data of
these patients were retrospectively collected and ana-
lyzed with approval of the Institutional Review Board
on Medical Ethics at Huazhong University of Science
and Technology. Baseline characteristics of patients
are listed in Table 1.HLATyping
Among all the 82 URDs, 66 were selected through
the Chinese Marrow Donor Program and 16 were
selected through the Buddhist Tzu Chi Stem Cells
Center. Most of the donor human leukocyte antigen
756 Biol Blood Marrow Transplant 18:754-762, 2012J. Fang et al.(HLA) typing results included data of HLA-A, -B, -C,
-DRB1, and -DQB1, but a small part of the results be-
tween 2002 and 2006 only contained data of HLA-A,
-B, and -DRB1. Therefore, in this study, only HLA-
A, -B, and -DRB1 data were collected to evaluate the
HLA disparity between donor-recipient pairs.
Of 82 donor-recipient pairs, 25 were 6 of 6 identi-
cal at allele or antigen level, 37 were 5 of 6 matched at
allele level, and 20 were #4 of 6 matched at the allele
level or single mismatch at the antigen level. Accord-
ingly, we divided the patients into an HLA 6 of 6
matched group, an HLA 5 of 6 matched group, and
an HLA #4 of 6 matched group when analyzing
GVHD onset and survival.Conditioning Regimen and Supportive Care
The conditioning regimens included total body
irradiation (8 Gy, on day 26) and cyclophosphamide
(Cy, 60 mg/kg/day i.v., from days 23 to22) in 11 pa-
tients. Forty-three patients received busulfan (Bu, 3.2
mg/kg i.v. in divided doses daily, from days 26
to 24), Cy (1.8 g/m2/day i.v., from days 23 to 22),
and 4-Methyl derivative of chlorethyl cyclohexyl
nitrosourea (Me-CCNU) (250 mg/m2) once on day
22. Nineteen patients had high-risk hematologic ma-
lignancies. Those patients received a combination of
BuCy and idarubicin (15 mg/m2/day, continuous infu-
sion for more than 20 hours on days211 to29) or eto-
poside (VP16, 40 mg/kg/day, on day 21). High-risk
hematological malignancies were defined as follows:
for acute lymphoblastic leukemia (ALL), any patient
with poor-risk cytogenetics [Ph, t(4;11), t(1;19)], age
$ 35 years, white blood cell (WBC) count .30 
109/L for B lineage and .100  109/L for T lineage
at diagnosis, or the time to achieve complete remission
.6 weeks [23]; for acute myeloid leukemia (AML), any
patient with delayed response to chemotherapy [24],
unfavorable karyotype [25-27], or a history of
preceding neoplasia and/or chemotherapy [28,29];
for myelodysplastic syndrome (MDS), any patient
scored as Intermediate-2 or high-risk according to
International Prognostic Score System (IPSS) [30].
Additional high-risk diseases included the accelerated
phase or blastic phase of chronic myeloid leukemia,
progressive lymphoma, and hybrid acute leukemia.
Nine patients received a combination of BuCy and
cytarabine. The conditioning regimen involved cytar-
abine (2 g/m2 on day 28) followed by Bu (3.2 mg/kg
i.v. in divided doses daily, on days 27 to 25), Cy
(1.8 g/m2 on days 24 to 23), and oral Me-CCNU
(250 mg/m2 on day 22).
To prevent seizures, phenytoin (100 mg) was
administered orally 3 times daily beginning 24 hours
before the first dose of Bu and continued until 24 hours
after the last dose. Antimicrobial prophylaxis consisted
of ganciclovir 5mg/kg twice daily from day210 to22,ciprofloxacin 500 mg twice daily, and oral fluconazol
from day 210 until day 175. Patients received
cotrimoxazole twice daily from the time of neutrophil
recovery to 6 months. CMV viral load was monitored
by polymerase chain reaction at least weekly within
100 days posttransplantation. CMV reactivation was
defined by positive CMV DNA detection in 2 consec-
utive blood samples.Collection of Hematopoietic Cells
Donor PBSCs were collected using standard mo-
bilization protocols. Granulocyte colony stimulation
factor (5-10 mg/kg once daily) was used to mobilize
peripheral blood. The peripheral blood progenitor
cells were harvested on day 4 and 5 after granulocyte
colony stimulation factor. The harvested cells were in-
fused without manipulation on the same day of
leukapheresis collection.Engraftment and Chimerism Assessment
Hematologic recovery, cytogenetic studies, bone
marrow aspirate, and biopsy were used to assess the
engraftment. Granulocyte engraftment was defined
as an absolute neutrophil count of 0.5  109/L or
more for 3 consecutive days, and the platelet count
needed to be above 20  109/L without transfusion
for 3 days. Chimerism was evaluated by polymerase
chain reaction–based analyses of variable numbers of
tandem repeats [31].GVHD Prophylaxis
All patients received GVHD prophylaxis consist-
ing of cyclosporine A (CsA), short-course methotrex-
ate, mycophenolate mofetil, and IL-2AR (basiliximab,
Simulect, Novartis Pharmaceuticals, East Hanover,
NJ, or daclizumab, Zenapax, Roche Pharmaceuticals,
Indianapolis, IN). Sixty recipients were given basilixi-
mab intravenously at a dose of 20 mg by 30-minute i.v.
infusion on day 0 (2 hours before transplantation) and
day 14. The remaining 22 recipients were adminis-
trated daclizumab intravenously at a dose of 1 mg/kg
on day 0 (2 hours before transplantation) and day
14. CsA was orally or i.v administered twice daily
starting on day 21 to maintain blood levels between
150 and 250 ng/mL; the dosage was adjusted to blood
levels and renal function. CsA was tapered by approx-
imately 5% per week from day 150 and discontinued
on day 1180 in the absence of grade II-IV aGVHD
and extensive chronic GVHD (cGVHD). Methotrex-
ate was given at a dose of 15 mg/m2 i.v. on day 11,
10 mg/m2 on days 13, 16, and 111, and followed
by folinic acid rescue. Mycophenolate mofetil was
given at a dose of 7.5 mg/kg orally twice daily from
days 17 to 135. Acute GVHD was graded according
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30 days were included in the analysis of aGVHD.
Chronic GVHD was defined according to standard
criteria [33]. A minimum of 100 days of follow-up
was the criterion evaluable for cGVHD.IL-2RAs-Related Toxicities
IL-2RAs-related toxicities were evaluated accord-
ing to the National Cancer Institute Common Toxic-
ity Criteria Version 3.0. Organ damage because
of GVHD and/or infectious complications was
excluded.Statistical Analysis
Evaluations were based on data available by July 15,
2010. Demographic factors were summarized using
percentage, median, and range value. Categoric vari-
ables were compared using the chi-square test or Fisher
exact test. Logistic regressionwas applied formultivar-
iate analysis of risk factors for grade II-IV aGVHDand
cGVHD. The cumulative probabilities of overall sur-
vival (OS) and disease-free survival (DFS) were esti-
mated by the Kaplan-Meier method. Differences
between the curves were tested for statistical signifi-
cance by the log-rank test. All tests were 2 tailed, and
a P value of\.05 was considered to indicate statistical
significance. Data was analyzed using SPSS software
(version 16.0, SPSS Inc., Chicago, IL).Table 2. Multivariate Analysis for Grade II-IV aGVHD and cGVHD
aGVHD Grade
OR 95% CI
Age (years)
30 or younger — —
Older than 30 0.438 0.124-1.552
Diagnosis
ALL — —
AML 0.585 0.155-2.210
CML 0.359 0.074-1.731
Other 0.251 0.028-2.228
Donor-recipient ABO blood type — —
Matched — —
Minor mismatched 0.459 0.103-2.048
Major mismatched 2.767 0.745-10.274
Donor-recipient HLA type
6 of 6 matched — —
5 of 6 matched 1.073 0.307-3.744
#4 of 6 matched 5.233 1.174-23.324
Interval from diagnosis to PBSCT, months
#6 months — —
>6 months 1.779 0.541-5.846
The disease status before PBSCT
Standard risk — —
High risk 1.592 0.491-5.162
Grade II-IV aGVHD
No — —
Yes — —
OR indicates odds ratio; ALL, acute lymphoblastic leukemia; AML, acute mye
antigen.RESULTS
Engraftment
All recipients obtained hematologic recovery. The
median time to neutrophil recovery was 12 days
(range: 8-23), whereas the median time to platelet
recovery was 14 days (range: 9-26). Analysis of
chimerism indicated that all patients achieved full
donor chimerism by day 130 after URD-PBSCT.GVHD
Acute onset ofGVHDoccurred in 62.2% (51 of 82)
patients; 22patients (26.8%)developedgrade I aGVHD
and 16 patients (19.5%) suffered grade II aGVHD.The
percentage of grade II-IV aGVHD and grade III-IV
aGVHD were 35.4% (29 of 82) and 15.9% (13 of 82),
respectively. Median onset time of aGVHD was 25
days posttransplantation (range: 10 to 88). Involved or-
gans included skin in 21 patients, intestinal tract in 14
patients, liver in 10 patients, and multiple organs in 6
patients. Among 82 patients, 75 patients were evaluable
for cGVHD. Limited cGVHD occurred in 13 patients
(17.3%) and extensive cGVHDdeveloped in 16patients
(21.4%). The median onset time of cGVHD was 145
days (range: 100-385) after transplantation.Risk Factors for GVHD
As shown in Table 2, multivariate analysis was per-
formed to evaluate risk factors for grade II-IV aGVHDfollowing URD-PBSCT
II-IV cGVHD
P OR 95% CI P
— — — —
0.201 2.738 0.815-9.200 0.103
— — — —
0.429 2.995 0.825-10.869 0.095
0.202 2.127 0.504-8.985 0.305
0.215 2.016 0.270-15.049 0.494
— — — —
— — — —
0.308 2.352 0.579-9.550 0.232
0.128 0.947 0.248-3.615 0.937
— — — —
0.912 2.613 0.766-8.917 0.125
0.030 0.909 0.189-4.383 0.906
— — — —
0.343 1.059 0.350-3.202 0.920
— — — —
0.438 1.320 0.416-4.191 0.638
— — — —
— 3.377 1.004-11.356 0.049
loid leukemia; CML, chronic myeloid leukemia; HLA, human leukocyte
Figure 1. Kaplan-Meier estimates of the cumulative probability
of 2-year OS and DFS in all 82 patients following URD-PBSCT. OS
indicates overall survival; DFS, disease-free survival; URD-PBSCT, unre-
lated donor-peripheral blood stem cell transplantation; SCT, stem cell
transplantation.
758 Biol Blood Marrow Transplant 18:754-762, 2012J. Fang et al.and cGVHD. Neither age, type of hematologic malig-
nancy, donor-recipient ABO blood type disparity,
interval from diagnosis to PBSCT, nor disease status
before PBSCT is identified as the risk factor for grade
II-IV aGVHD. However, if the donor-recipient HLA
type disparity increases to 2 or more at the allele level,
as well as single mismatch at antigen level on HLA-A,
-B, and -DRB1, the risk of grade II-IV aGVHD signif-
icantly enhances to 5.2-fold (P 5 .03). Furthermore,
the onset of grade II-IV aGVHD is also associated
with a 3.4-fold (P 5 .049) risk of cGVHD.Figure 2. Kaplan-Meier estimates of the cumulative probability of 2-year OS (
group versus HLA 5/6 matched group, P 5 .432; HLA 6 of 6 matched group ve
versus HLA #4 of 6 matched group, P 5 .655. (B) HLA 6 of 6 matched group
versus HLA #4 of 6 matched group, P 5 .924; HLA 5 of 6 matched group v
transplantation; 6 of 6 matched, HLA 6 of 6 matched; 5 of 6 matched, HLA 5 o
DFS, disease-free survival.Survival and Outcome
During a median follow-up of 16.5 months (range:
2-72), 66 patients survived and 16 patients died. In all,
TRMwas 13.4% (11 of 82) with amedian onset time of
3 months posttransplantation (range; 2-23). The prin-
cipal causes of TRM included aGVHD (n 5 5),
cGVHD (n 5 2), invasive fungal infection (n 5 2),
bacterial pneumonia (n 5 1), and hepatic veno-
occlusive disease (n 5 1). Relapse occurred in 7
patients (8.5%) with a median onset time of 6 months
posttransplantation (range: 2.5-14). Among those re-
lapsed patients, 5 patients subsequently died of disease
progression, 2 patients received combination chemo-
therapy, and the remainder survived. As shown in
Figure 1, the estimated probabilities of 2-year OS
and 2-year DFS are 77.1% (95% confidence interval
[CI], 66.5%-87.7%) and 72.2% (95% CI, 59.9%-
84.5%), respectively.GVHD and Survival According to HLAMatching
Status
Considering the different HLA matching status,
grade II-IV aGVHD onset was only 28% in the
HLA 6 of 6 matched group, 27% in the HLA 5 of
6 matched group, but significantly increased to 60%
in the HLA #4 of 6 matched group (P 5 .031 and
P 5 .015, respectively). No significant difference was
observed between the HLA 6 of 6 matched group
and the HLA 5 of 6 matched group (P 5 .094). The
occurrence of grade III-IV aGVHD in the HLA #4
of 6 matched group was 35%, which was higher than
that in the 5 of 6 matched group (8%) and the
HLA 6 of 6 matched group (12%). But only the differ-
ence between the HLA#4 of 6 matched group and the
HLA 5 of 6 matched group was significant (P5 .024).A) and DFS (B) in different HLA matching groups. (A) HLA 6/6 matched
rsus HLA #4 of 6 matched group, P 5 .835; HLA 5 of 6 matched group
versus HLA 5 of 6 matched group, P 5 .283; HLA 6 of 6 matched group
ersus HLA #4 of 6 matched group, P 5 .387. SCT indicates stem cell
f 6 matched; 4 of 6 matched, HLA#4 of 6 matched; OS, overall survival;
Figure 3. Kaplan-Meier estimates of the cumulative probability of 2-year OS (A) and DFS (B) in basiliximab or daclizumab group, P5.336 and P5.296,
respectively. SCT indicates stem cell transplantation; OS, overall survival; DFS, disease-free survival.
Biol Blood Marrow Transplant 18:754-762, 2012 759Effects of IL-2 Receptor Antagonists against GVHDThere was no statistical discrepancy in cGVHD rates
among the 3 groups. As shown in Figure 2, the 2-
year OS (A) and 2-year DFS (B) in 3 groups are not sig-
nificantly different.
Infectious Complications
Forty patients experienced bacterial infection
posttransplantation (48.8%), and 1 patient died of se-
vere bacterial pneumonia. Ten patients developed
probable or proven invasive fungal infection, and 2 pa-
tients died. The rate of CMV reactivation was 47.6%
(39 of 82). Only 1 patient suffered CMV pneumonia.
The patient with CMV disease was treated with ganci-
clovir 5 mg/kg twice daily for 21 days and then fol-
lowed with ganciclovir 5 mg/kg daily until CMV
DNAdetection turned to negative, with a combination
of intravenous immunoglobulin. The anti-CMV ther-
apy was successful, thus CMV pneumonia was man-
aged. Moreover, although Epstein-Barr virus was not
monitored in those patients, there was no clinical evi-
dence of PTLD.
Daclizumab versus Basiliximab
Among 82 recipients, 22 recipients received dacli-
zumab, whereas 60 recipients received basiliximab.
There was no significant difference in clinical charac-
teristics in the patients between the basiliximab and da-
clizumab groups (data not shown). The onset of grade
II-IV aGVHD was not significantly different between
the daclizumab and basiliximab groups (41% versus
33.3%, P 5 .525); neither was the onset of grade III-
IV aGVHD (13.6% versus 16.7%, P 5 .74). Interest-
ingly, the occurrence of cGVHD was significantly
lower in the basiliximab group (30.4%) than that in
the daclizumab group (63.2%, P5 .011), especially ex-
tensive cGVHD (14.3% versus 42.1%, P5 .02). In all,
TRMwas 13.3% (8 of 60) in the basiliximab group, but
13.6% (3 of 22) in the daclizumab group (P 5 .972).
Relapse occurred in 2 of 60 recipients (3.3%) in thebasiliximab group, but 3 of 22 recipients (13.6%) in
the daclizumab group (P 5 .117). As indicated in
Figure 3, the 2-year OS (A) and 2-year DFS (B) in
the basiliximab group seem superior (77.3%, 95%
CI, 63%-91%; 75.5%, 95% CI, 61.4%-89.6%) than
those in the daclizumab group (72.7%, 95% CI,
54%-91%; 65.5%, 95%CI, 52%-79%), but the differ-
ences are not significant (P 5 .336 and P 5 .296,
respectively).
Side Effects of IL-2RAs
Either basiliximab or daclizumab was tolerable
with moderate side effects. Nausea and vomiting
occurred in 20 patients (24.4%), followed by diarrhea
in 11 patients (13.4%) and constipation in 4 patients
(4.9%). Those side effects were restricted to grade I-
II. No related infection was observed. There were no
other adverse effects developed as well, such as hema-
tologic, cardiac, liver, nephro, and neurologic toxicity.DISCUSSION
In the present study, we retrospectively analyzed
the prophylactic effects of IL-2RAs against GVHD
following URD-PBSCT. Our results first suggest
that basiliximab or daclizumab effectively prevents
GVHD in URD-PBSCT. According to the literature,
the occurrence of aGVHD ranges from 30% to 80%
postallogeneicHSCT [17]. The risk of GVHD also in-
creases in URD-HSCT. Grade II-IV aGVHD occurs
in 43% to 70% of matched URDmarrow transplanta-
tions, and in 63% to 95% of HLA 1 antigen-
mismatched URD transplantations [34]. Moreover,
cGVHD is reported in more than 55% of matched
URD transplantion recipients and as many as 80% of
HLA 1 antigen-mismatched URD transplantations
[34]. Here we reported that grade II-IV and grade
III-IV aGVHD were observed in 35.4% and 15.9%
of patients post-URD-HSCT respectively, whereas
760 Biol Blood Marrow Transplant 18:754-762, 2012J. Fang et al.cGVHD only occurred in 38.7% of patients. Thus,
these results indicate that IL-2RAs-intensified
GVHD prophylaxis leads to adequate immunosup-
pression following URD-HSCT, which coincides
with the results from a previous study on haploidenti-
cal bone marrow transplantation [21].
Because of the limitation of retrospective study, we
found that only 11 patients did not receive IL-2RAs but
received ATG for intensifying the GVHD prophylaxis
regimen following URD-PBSCT when we collected
data in our department. Moreover, there was a signifi-
cant difference in clinical characteristics in the patients
between the IL-2RAs and the no IR-2RAs (ATG)
groups. Therefore, we considered that the collected
data did not support providing a control group in the
present study. However, we summarized the published
literature that studied the ATG-intensified GVHD
prophylaxis in URD-HSCT as a comparison. It has
been reported that grade II-IV aGVHD occurs in
19%-51% patients receiving ATG-intensified
GVHD prophylaxis regimens, while 11%-15%
patients suffer grade III-IV aGVHD. The onset of
cGVHD is 16%-44% in the ATG group, but up to
76% in the no-ATG group [3,4,6,35,36].
Considering our results mentioned above, it is
suggested that basiliximab or daclizumab has
comparable immunosuppressive activity with ATG as
an intensifying agent to GVHD prophylaxis.
Moreover, our results also suggest that an IL-2R
blockade does not increase the risk of infection when
enhancing immunosuppression following URD-
HSCT. In vivo T cell depletion with ATG decreases
GVHD, but results in delayed immune reconstitution,
leaving the recipient more susceptible to infections
[4,5,7,37]. However, daclizumab or basiliximab binds
specifically to the IL-2R of activated T cells with
high affinity and only selectively depletes the alloreac-
tive donor lymphocytes, without affecting the resting
T cells, which are important for preventing infectious
complications [38,39]. Similarly, it is also addressed
that daclizumab or basiliximab treatment has a lower
incidence of infectious deaths than ATG treatment
[40]. Bacigalupo et al. [4] reported that the rate of
infectious death was 7% in 7.5 mg/kg ATG but 30%
in the 15 mg/kg ATG group when ATG was adminis-
tered to prevent GVHD. The CMV reactivation was
similar in the ATG and non-ATG groups (67% versus
68%). Pidala et al. [41] demonstrated that the rate of
infectious death was 13.3% when 7.5 mg/kg ATG
was administered to prevent GVHD. The overall cu-
mulative incidence of CMV reactivation was 60%,
and comfirmed CMV organ involvement was present
in 15.6% (7 of 45) of patients. Here in our study, the
rate of infectious death was only 3.7%. CMV reactiva-
tion was observed in 47.6% of patients. Only 1 patient
developed CMVdisease and was cured with anti-CMV
therapy. Moreover, no PTLD was observed in ourstudy. These results suggest that additional adminis-
tration of daclizumab or basiliximab reinforces
GVHD prophylaxis without increasing infections or
infection-related deaths.
But it remains arguable whether IL-2RAs affects
graft-versus-leukemia effects. As previously reported,
IL-2R monoclonal antibody (33B3.1), a rat antibody
directed against IL-2R, significantly impairs
leukemia-free survival mainly because of increasing
late relapse [42]. Nevertheless, inolimomab (BT563,
Leucotac, Biotest, Piscataway, NJ), a murine mono-
clonal antibody against CD25, does not enhance the
10-year leukemia-free survival after URD-bone mar-
row transplantation [18]. Furthermore, daclizumab
or basiliximab administration results in low relapse
rates during HSCT [17-20,43]. The discrepancy of
CD25 monoclonal antibody types may account for
the arguments. In our study, the relapse rate was
only 8.5%, which was lower than that in the ATG
group (18%-45%) according to published data
[3,4,6,35,36]. Thus, it is suggested that daclizumab
or basiliximab does not affect graft-versus-leukemia
as an intensifying GVHD prophylactic agent in
HSCT. Moreover, daclizumab or basiliximab admin-
istration results in favorable outcome. It has been
reported that long-term OS and DFS achieves 56%
and 51.6%, respectively, in the ATG group
[3,4,6,35,36]. In research on HLA-identical sibling
transplantation, the 2-year OS is 72%, and ATG
administration in addition to the standard GVHD
prophylaxis regimen results in comparable outcome
(2-year OS, 71%) post-HLA-mismatched related do-
nor or haploidentical HSCT [44]. Inspiringly, our re-
sults showed that the 2-year OS and DFS also rose to
77.1% and 72.2%, respectively. The explanations for
the favorable outcome can be the effective GVHD
prophylaxis without increasing the risk of relapse,
infections, and graft failure by IL-2RAs.
We evaluated the effects of IL-2RAs on GVHD in
different HLA matching status. In the present study,
the rate of grade II-IV aGVHD was similar in the
HLA 6 of 6 matched group and the 5 of 6 matched
group, but significantly higher in the#4 of 6 matched
group. However, the 2-year OS and DFS were not sig-
nificantly different among these 3 groups. These re-
sults suggest that specific the IL-2R blockade
effectively prevents aGVHD during URD-PBSCT,
especially in HLA identical or only 1 allele mis-
matched recipients. Furthermore, IL-2RAs benefits
the outcome, even for those recipients with 2 or
more HLA disparities.
We also evaluated the immunosuppressive effect of
daclizumab versus basiliximab in HSCT because there
was no published data. This type of comparable study
has been performed in renal transplantation. Most
studies suggest that there are no significant differences
in acute rejection, graft function, survival, and safety
Biol Blood Marrow Transplant 18:754-762, 2012 761Effects of IL-2 Receptor Antagonists against GVHDof induction therapy between basiliximab and daclizu-
mab [45-48]. Only Lin et al. [49] suggested that basilix-
imab wasmore effective than daclizumab in preventing
acute rejection following renal transplantation. In our
study, basiliximab presented the same prophylactic ef-
fects on aGVHD but superior prophylactic effects on
cGVHD than daclizumab. Nevertheless, the underly-
ingmechanisms remain unclear. There are few hints. It
is documented that 5 doses of daclizumab saturates the
CD25 subunit for approximately 120 days after trans-
plantation [50]. The long-term immunosuppressive ef-
fect of daclizumab may contribute to preventing
cGVHD. In vitro study also indicates that daclizumab
provides the synergistic activity of inhibiting T cell
proliferation with CsA, whereas basiliximab shows
only subadditive activity [51]. Thus, it seems that da-
clizumab has more advantages than basiliximab. How-
ever, our results showed that daclizumab had equal
effects on aGVHD prophylaxis but inferior effects
on cGVHD than basiliximab. Therefore, further stud-
ies are needed to explore the mechanisms underlying
the different preventive activities against GVHD be-
tween daclizumab and basiliximab.CONCLUSION
On the whole, we provide the first evidence that an
IL-2R blockade with daclizumab or basiliximab is
efficient and safe in preventing GVHD following
URD-PBSCT, and contributes to a favorable out-
come. IL-2RAs can be the alternative immunosuppres-
sive agents for intensifying GVHD prophylaxis in
URD-HSCT. Basiliximab has similar effects on pre-
venting aGVHD but superior activities against
cGVHD than daclizumab. It should be noted that
this study is retrospective; thus, further prospective
and randomized control studies are needed.ACKNOWLEDGMENTS
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